logo
    Docs
 

Unmet Medical Need: Efo/round Cell Liposarcoma


1. Disease Summary:

Round cell liposarcoma (RCLS) is a rare and aggressive subtype of myxoid liposarcoma, which is itself a type of soft tissue sarcoma. It is characterized by a predominance of round cells in the tumor, which contributes to its aggressive behavior and poor prognosis. RCLS typically occurs in adults and is often found in deep soft tissues, such as the retroperitoneum or limbs. The disease is associated with a high rate of metastasis and recurrence, making it particularly challenging to treat.

2. Global Prevalence and Disease Burden:

Liposarcomas, including RCLS, account for approximately 1% of all adult malignancies, with RCLS representing a smaller subset of these cases. The estimated incidence of myxoid/round cell liposarcoma is about 0.5 to 1.0 per 100,000 individuals per year. The 5-year survival rate for RCLS is approximately 54.9%, which is lower than other subtypes of liposarcoma, such as well-differentiated liposarcoma (82.3%) and myxoid liposarcoma (76.4%) (PMID: 32374488). The economic burden of RCLS is significant due to the costs associated with treatment, management of complications, and loss of productivity among affected individuals.

3. Unmet Medical Need:

Despite advancements in cancer treatment, there remains a substantial unmet medical need for patients with round cell liposarcoma. Key areas of unmet need include:
  • Limited Effective Treatments: Current therapies, including chemotherapy and radiation, often yield suboptimal results. The overall response rate to first-line chemotherapy regimens is around 40% for anthracycline-based treatments, and only 20% for trabectedin (PMID: 36853469). Many patients experience disease progression despite treatment.
  • High Recurrence Rates: RCLS has a high rate of local recurrence and metastasis, with studies showing that approximately 20% of patients experience distant metastasis within five years (PMID: 22052112). This necessitates the development of more effective therapeutic strategies.
  • Lack of Targeted Therapies: There is a significant gap in targeted therapies specifically designed for RCLS. While immunotherapies targeting antigens like NY-ESO-1 are being explored, they are not yet widely available or proven effective in clinical practice (PMID: 23881508).
  • Quality of Life Considerations: The impact of RCLS on patients' quality of life is not well-documented, and there is a need for studies that assess patient-reported outcomes and the psychosocial effects of living with this aggressive cancer.

4. Current Treatment Options:

Current treatment options for round cell liposarcoma include:
  • Surgery: Surgical resection remains the primary treatment for localized disease. However, achieving clear margins can be challenging due to the tumor's aggressive nature and location.
  • Chemotherapy: First-line treatment typically involves anthracycline-based regimens, such as doxorubicin or ifosfamide. However, the effectiveness of chemotherapy is variable, and many patients do not respond adequately.
  • Radiation Therapy: Radiation is often used in conjunction with surgery to improve local control, particularly in cases where complete resection is not possible. However, it does not significantly impact overall survival.
  • Emerging Therapies: New treatment modalities, including immunotherapies and targeted therapies, are being investigated in clinical trials. For example, afamitresgene autoleucel (afami-cel) is being evaluated for its efficacy in treating RCLS (NCT04044768).

5. Current Clinical Trials:

Several clinical trials are currently exploring new treatment options for round cell liposarcoma:
  • SPEARHEAD-1 Study: This phase 2 trial is evaluating the safety and efficacy of afamitresgene autoleucel in patients with advanced myxoid/round cell liposarcoma (NCT04044768). Early results suggest promising efficacy, but further studies are needed to confirm these findings.
  • NY-ESO-1 Targeting Trials: Trials are underway to assess the effectiveness of T-cell therapies targeting the NY-ESO-1 antigen, which is expressed in many RCLS tumors. These therapies aim to harness the immune system to fight cancer more effectively.

6. Additional Context:

The landscape of treatment for round cell liposarcoma is evolving, but significant challenges remain. The rarity of the disease contributes to limited research funding and fewer clinical trials, which hampers the development of effective therapies. Additionally, the aggressive nature of RCLS necessitates a multi-faceted approach to treatment, including surgery, chemotherapy, and emerging therapies. Addressing the unmet medical needs of patients with RCLS will require concerted efforts in research, clinical trials, and patient advocacy to improve outcomes and quality of life for those affected by this challenging disease.